Arvinas, Inc.
$7.21
The Read: 7% on average around investor catalysts including June 15 conferences and investor days, with notable outsized rallies of over 50% driven by FDA approval of VEPPANU and major licensing deals despite mixed earnings and strategic pivots.
Price
Overlays
Panel
ARVN
Hover to view data
No Data